News | August 13, 2021
Wockhardt to manufacture and supply Sputnik V
Sputnik V is a two-dose shot and has an efficacy of 91.6% against COVID 19
Sputnik V is a two-dose shot and has an efficacy of 91.6% against COVID 19
A new market study published by Global Industry Analysts (GIA), released its report titled, ``Healthcare Supply Chain Management—Global Market Trajectory & Analytics.’’ We present excerpts from the report
This work has been published in the journal ‘ACS applied materials and interface’
The scheme incentivizes the manufacturing of patented drugs and other high value drugs at an incentive rate of 10% of incremental sales
The govt has rolled out three schemes for promoting the manufacture of API
The company has an outlay of Rs 120-140 crore as R & D expense for FY 22
The company confirms an upward revision to its 2021 Outlook, reflecting the expectation to achieve mid-teens CER sales growth
The company reported total income of Rs.1215.73 crores during the period ended June 30, 2021.
The first quarter performance reflects growth across all its business divisions as the company continued to operate at normal levels
As per the agreement, Lonza will provide commercial-scale manufacture of monoclonal antibodies
Subscribe To Our Newsletter & Stay Updated
